GSK plc (NYSE:GSK – Get Free Report) has been given an average rating of “Buy” by the eight research firms that are covering the company, Marketbeat reports. Three investment analysts have rated the stock with a hold rating, two have assigned a buy rating and three have given a strong buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $50.00.
A number of research analysts recently weighed in on GSK shares. Citigroup raised GSK to a “strong-buy” rating in a report on Monday, June 24th. Argus raised shares of GSK to a “strong-buy” rating in a research report on Wednesday, August 7th. Jefferies Financial Group lifted their target price on shares of GSK from $52.50 to $53.00 and gave the stock a “buy” rating in a report on Tuesday, July 2nd. The Goldman Sachs Group assumed coverage on shares of GSK in a research note on Thursday, May 30th. They issued a “neutral” rating and a $47.00 price target on the stock. Finally, UBS Group downgraded shares of GSK from a “buy” rating to a “neutral” rating in a research report on Monday, July 8th.
Check Out Our Latest Stock Analysis on GSK
Institutional Inflows and Outflows
GSK Price Performance
Shares of NYSE GSK opened at $41.21 on Friday. GSK has a twelve month low of $33.67 and a twelve month high of $45.92. The company has a market cap of $85.41 billion, a PE ratio of 14.93, a price-to-earnings-growth ratio of 1.32 and a beta of 0.64. The business’s 50 day moving average price is $39.73 and its two-hundred day moving average price is $41.44. The company has a quick ratio of 0.58, a current ratio of 0.82 and a debt-to-equity ratio of 0.99.
GSK Increases Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 10th. Shareholders of record on Friday, August 16th will be paid a $0.3843 dividend. This is a boost from GSK’s previous quarterly dividend of $0.38. The ex-dividend date of this dividend is Friday, August 16th. This represents a $1.54 annualized dividend and a yield of 3.73%. GSK’s payout ratio is 54.71%.
GSK Company Profile
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Featured Articles
- Five stocks we like better than GSK
- What Are Dividend Champions? How to Invest in the Champions
- Brinker International’s Price Dip is an Appetizing Entry Point
- What Is WallStreetBets and What Stocks Are They Targeting?
- 3 Stocks That Could Beat the September Blues
- How to Use Stock Screeners to Find Stocks
- Canopy Growth Stock: Can It Sustain Recent Gains?
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.